Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Diabetes Mellitus, Type 2
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study protocol is to assess the effect of concurrent aerobic and resistance training in patients with type 2 diabetes on vitamin D treatment

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Other: Resistance training — Sarcoplasm stimulating training system. This program will run for a total of 16 weeks and three sessions a week. This exercise plan is designed in three 5-week periods plus a familiarization session.

Primary Outcomes

  • Change in Homeostatic Model Assessment of Insulin Resistance (HOMA IR) (Beginning of the study and after 4 months)
  • Change in Homeostasis model assessment of β-cell function (HOMA-β) (Beginning of the study and after 4 months)
  • Change in serum levels of Hemoglobin A1c. (Beginning of the study and after 4 months)
  • Change in serum lipid profile (Beginning of the study and after 4 months)
  • Change in weight (Beginning of the study and after 4 months)
  • Change in waist circumference (Beginning of the study and after 4 months)
  • Change in Body Mass Index (BMI) (Beginning of the study and after 4 months)
  • Vitamin D (Beginning of the study)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-01
Completion: 2027-12-31
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Ramon Llull
Collaborators: University of Barcelona, Islamic Azad University, Sanandaj, Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina, Institut Català de la Salut
Principal Investigators:
  • Joel Montane, PhD (PRINCIPAL_INVESTIGATOR) - Universitat Ramon Llull
Contact Information
Study Contact:
Joel Montane, PhD
932533256
joelmm@blanquerna.url.edu
Interventions
  • Other: Resistance training — Sarcoplasm stimulating training system. This program will run for a total of 16 weeks and three sessions a week. This exercise plan is designed in three 5-week periods plus a familiarization session.
Study Locations (1 sites)
CAP Sant Rafael, Barcelona, Spain
Eligibility Criteria
Inclusion Criteria: * Adults (females or males) older than 18 years old with a diagnosis of T2D in the clinic database * Patients who have been taking the combination therapy of metformin + sodium-glucose transport protein 2 inhibitors (iSGLT2), as recommended by the redGDPS 2023, with stable medication for the past 6 months. * Diabetic patients taking prescribed VitD treatment for at least 6 months (intervention group) and diabetic patients not taking prescribed VitD (control group) * Patients who signed the informed consent * Patients capable of performing mild to moderate physical activity (to walk steadily and independently for at least 6 minutes) Exclusion Criteria: * Patients taking other medication different than metformin + iSGLT2 (including combinations and insulin) * Patients taking polyvitaminic supplementation at the inclusion for at least, 1 month before the intervention * Female subjects who are pregnant * Patients who did not sign the informed consent
Conditions Maturity-Onset Diabetes of the Young (MO...
Phase Not Applicable
Enrollment 1500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observation is to establish a complete registry for the clinical manifestations, environment, genetic, and other related gene variation information of young-onset diabetic patients. Moreover, according to the physiological and pathological mechanisms of different genes, the impact on the clinical characteristics of diabetes, the therapeutic response to drugs, and the impact on complications will be analyzed. The main questions are: 1. The distribution of different types of MODY 2. The phenotypes and clinical characteristics of different types of MODY 3. Response to antidiabetic drugs among different types of MODY Once the participant is enrolled, their questionnaire information (including disease course and development, health history, family history, drug history, etc.), medication, outpatient/inpatient medical history, etc. will be collected and logged in. Blood and urine samples will also be collected for biochemical tests genetic testing, etc. At the same time, the investigators will conduct a continuous follow-up on a regular basis (3 months, 6 months, 12 months, 24 months, and 5 years after the study subject is enrolled). Young-onset type 2 diabetes will be compared to see the difference in clinical presentations and responses to antidiabetic drugs.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Glucose control (3 months)
  • Genetic testing for evaluate the different types of MODY (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-05-22
Completion: 2028-05-21
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Taichung Veterans General Hospital
Collaborators: National Health Research Institutes, Taiwan
Principal Investigators:
  • Yi-Jing Sheen, MD. PHD (PRINCIPAL_INVESTIGATOR) - Division of Endocrinology and Metabolism in Taichung Veterans General Hospital
Contact Information
Study Contact:
Yi-Jing Sheen, MD. PHD
886-4-2359-2525
docmedjean@gmail.com
Yi-Jing Sheen, MD. PHD
886-4-2359-2525
docmedjean@gmail.com
Taichung veterans general hospital
Wayne H-H Sheu, MD. PHD
Taichung veterans general hospital
Interventions
N/A
Study Locations (1 sites)
Taichung veterans general hospital, Taichung, 407 Taiwan
Eligibility Criteria
Inclusion Criteria: 1. Case Group Diagnosis of diabetes at or before 25 years of age. BMI (Body Mass Index) of 25 kg/m² or lower. Having at least one parent diagnosed with type 2 diabetes. 2. Family Group Direct blood relatives of the case group, including brothers and sisters of the case group, who have contacted the research team through the subjects. Expressing willingness to participate in this study after granting informed consent. 3. Control Group Diagnosis of diabetes occurred at or before the age of 40, and the individual lacks typical MODY (Maturity-Onset Diabetes of the Young) characteristics. At least one parent has been diagnosed with type 2 diabetes. Exclusion Criteria: 1. Confirmed Diagnosed with type 1 diabetes. 2. Under 18 years of age. 3. Unable to personally provide informed consent. 4. Patients with unrelieved leukemia. 5. Patients who have undergone chemotherapy or radiation therapy for cancer within the last 12 months. 6. Cases that have received a blood transfusion within the last six months. 7. Unwilling or unable to continue treatment follow-up at this hospital.
Conditions Gestational Diabetes Mellitus in Pregnan...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

To determine the effect of using a mobile app versus paper logs on compliance and percentage in range blood sugars in monitoring blood sugar in pregnant women with diabetes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: OneTouch Reveal application — Evaluate if compliance with glucose logging and percentage of in range glucoses changes with use of a mobile application instead of paper logging

Primary Outcomes

  • Compliance (4 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-06-01
Completion: 2027-01-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Carolyn Zahler-Miller
Principal Investigators:
  • Rebecca Keipper, MD (PRINCIPAL_INVESTIGATOR) - Augusta University
Contact Information
Study Contact:
Rebecca Keipper, MD
7067212541
rkeipper@augusta.edu
Carolyn M Zahler-Miller, MD
7067212543
czahlermiller@augusta.edu
Carolyn M Zahler-Miller
706-721-2542
czahlermiller@augusta.edu
Augusta University
Interventions
  • Behavioral: OneTouch Reveal application — Evaluate if compliance with glucose logging and percentage of in range glucoses changes with use of a mobile application instead of paper logging
Study Locations (1 sites)
Augusta University, Augusta, Georgia 30912 United States
Eligibility Criteria
Inclusion Criteria: * 18 years and older * Verified intrauterine pregnancy * At least 12 weeks gestation * Diagnosed with either type 2 diabetes mellitus or gestational diabetes mellitus. Exclusion Criteria: * Patients with less than 4 weeks anticipated to be remaining in pregnancy * Pre-existing use of a continuous glucose monitor or other mobile application for glucose tracking * Type 1 diabetes mellitus * Non-English speaking patients
Conditions Acute Exacerbation of Chronic Obstructiv...
Phase Not Applicable
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Interoception refers to the process of perceiving and interpreting internal physiological signals and plays a central role in symptom perception. In conditions with a high symptom burden such as chronic obstructive pulmonary disease (COPD), clinical features including dyspnea perception, depression, and sleep quality may be influenced not only by disease severity but also by the interpretation of internal bodily signals. Recent evidence suggests that respiratory-related internal signals are transmitted to the central nervous system through multiple afferent pathways and integrated within cortical and subcortical networks, contributing to subjective experiences such as dyspnea. In this context, dyspnea perception may arise from the interaction between disease severity and interoceptive processes. Depressive symptoms and impaired sleep quality are also closely associated with interoceptive processes and may contribute to the perception of respiratory symptoms. However, studies simultaneously examining interoception, disease severity, dyspnea perception, depression, and sleep quality in hospitalized patients with acute COPD exacerbation are limited. This prospective, observational, cross-sectional study will include 50 individuals aged 40 years and older who are hospitalized with acute COPD exacerbation in a Chest Diseases clinic. Data will be collected at a single time point when patients are clinically stable, without interfering with routine clinical care. Participants will be recruited using a consecutive sampling method. Sociodemographic and clinical data will be obtained from patient records and a structured data collection form. Disease severity will be assessed using oxygen requirement, respiratory rate, oxygen saturation, and arterial blood gas values when available. Interoception will be evaluated using the Multidimensional Assessment of Interoceptive Awareness (MAIA-2). Symptom burden will be assessed with the COPD Assessment Test (CAT), dyspnea with the Modified Medical Research Council (mMRC) scale, sleep quality with the Richards-Campbell Sleep Questionnaire (RCSQ), and depressive symptoms with the Hospital Anxiety and Depression Scale - Depression subscale (HADS-D). Statistical analyses will be performed using IBM SPSS Statistics software. Relationships between variables will be analyzed using Pearson or Spearman correlation depending on data distribution, with a significance level of p\<0.05.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: No Intervention: Observational Cohort — Participants' sleep quality, COPD symptom burden, dyspnea severity, anxiety and depression levels, and interoceptive processing will be assessed cross-sectionally.

Primary Outcomes

  • Interoception Assessment (baseline)
  • COPD Symptom Burden Assessment (baseline)
  • Dyspnea Severity Assessment (baseline)
  • Sleep Quality Assessment (baseline)
  • Anxiety and Depression Assessment (baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-07-20
Completion: 2026-11-01
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Saglik Bilimleri Universitesi
Principal Investigators:
  • Gamze Koyutürk, Asst Prof (PRINCIPAL_INVESTIGATOR) - Topkapı University
  • Mehmet Burak Uyaroğlu, Asst Prof (STUDY_DIRECTOR) - Fenerbahce University
  • Hüsna Güzel (STUDY_CHAIR) - Fenerbahce University
Contact Information
Study Contact:
Gamze Koyutürk, PhD
+905065798671
gamzealtinkaynak@gmail.com
Mehmet Burak Uyaroğlu, Asst Prof
Gamze Koyutürk, Asst. Prof
gamzekoyuturk@topkapi.edu.tr
Goztepe Prof Dr Suleyman Yalcin City Hospital
Interventions
  • Other: No Intervention: Observational Cohort — Participants' sleep quality, COPD symptom burden, dyspnea severity, anxiety and depression levels, and interoceptive processing will be assessed cross-sectionally.
Study Locations (1 sites)
Goztepe Prof Dr Suleyman Yalcin City Hospital, Istanbul, Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Physician-confirmed diagnosis of acute exacerbation of COPD with hospitalization * Age 40 years or older * Conscious and able to communicate * Willing to participate and provide written informed consent Exclusion Criteria: * Presence of delirium or severe cognitive impairment * Requirement for invasive mechanical ventilation * Clinical instability preventing safe administration of assessment tools * History of severe neurological or psychiatric disorders * Any history of malignancy * Presence of pneumonia * History of stroke
Conditions Advanced Solid Tumor
Phase PHASE1, PHASE2
Enrollment 499
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a study to evaluate the safety and potential anti-tumor activity of an investigational drug called ARV-6723, in participants with advanced solid tumors. This is an open-label study which means that participants and study staff will know that all participants will receive ARV-6723. The investigational drug ARV-6723 will be given as an oral tablet on its own and also in combination with other drugs. Researchers think that ARV-6723 can help the body's immune system to better recognize, attack, and destroy cancer cells in adults with advanced solid tumors. ARV-6723 is an investigational drug, and this is the first time ARV-6723 will be used in humans. Depending on the treatment assignment, the investigational drug, ARV-6723, will be given as an oral tablet either on its own (monotherapy) or in combination with pembrolizumab, either through a vein (intravenously or IV) or through an injection beneath the skin (subcutaneously or SQ). This study will include multiple parts: In Part A1 (Phase 1a), different small groups of participants will receive lower to higher doses of ARV-6723 as monotherapy or in combination with standard-dose of pembrolizumab. In Part A2 (Phase 1b), two groups of participants with specific tumor indication(s) (TBD) will receive one of two doses selected based on information from Part A1. Details of Part B will be determined based on information generated from Part A.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: ARV-6723 — Oral daily dose of ARV-6723 at an assigned dose.
  • Drug: Pembrolizumab — IV infusion or SQ injection Q3W at an assigned dose.
  • Drug: SOC — Investigator's choice of SOC drugs.

Primary Outcomes

  • Part A1: Number of Dose-Limiting Toxicities (DLTs) of ARV-6723 (21 days from first ARV-6723 administration)
  • Part A1: Number of Participants With Adverse Events (AEs) (From the first dose of ARV-6723 through at least 28 days after the last dose (up to approximately 4.7 years))
  • Part A2: Number of Participants With AEs (From the first dose of ARV-6723 through at least 28 days after the last dose (up to approximately 4.7 years))
  • Part A2: Overall Response Rate (ORR) by computed tomography/magnetic resonance imaging (CT/MRI) Using Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) Criteria Per Investigator Assessment (Approximately 24 months)
  • Part B: ORR by CT/MRI using RECIST v1.1 Criteria Per Investigator Assessment (Approximately 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2026-07-29
Completion: 2032-03-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 499 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Arvinas Inc.
Contact Information
Study Contact:
Arvinas Inc.
+1 203 691 1115
ARV-6723-101-ClinicalContacts@arvinas.com
Interventions
  • Drug: ARV-6723 — Oral daily dose of ARV-6723 at an assigned dose.
  • Drug: Pembrolizumab — IV infusion or SQ injection Q3W at an assigned dose.
  • Drug: SOC — Investigator's choice of SOC drugs.
Study Locations (3 sites)
Clinical Trial Site, Huntersville, North Carolina 28078 United States
Clinical Trial Site, San Antonio, Texas 78229 United States
Clinical Trial Site, Fairfax, Virginia 22031 United States
Eligibility Criteria
Inclusion Criteria: Part A1 dose escalation and A2 dose optimization: Participants must meet all of the following criteria: * Have a histologic or cytologic diagnosis of unresectable or metastatic solid tumor malignancy. * Have previously received at least one prior therapy targeting programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), cytotoxic T-lymphocyte antigen 4 (CTLA-4), lymphocyte-activation gene 3 (LAG-3), and/or another T-cell co-stimulatory or immune checkpoint pathway, in any treatment setting (including neoadjuvant or adjuvant). * Have received prior SOC therapy appropriate for their disease type and stage and have no remaining available treatment options with established clinical benefit; or, in the opinion of the investigator, are unlikely to tolerate or derive clinically meaningful benefit from appropriate SOC therapy; or have declined SOC therapy. * Participants must have demonstrated radiographic progression and have at least 1 measurable lesion per RECIST v1.1 that has not been previously irradiated or has demonstrated progression of disease since radiation therapy. * ECOG PS 0 or 1 or equivalent. Participants with ECOG PS 2 may be considered upon discussion with the Sponsor Medical Monitor. * Participants with adequate organ function. Exclusion Criteria: Exclusion Criteria (Part A) * Active brain metastases (new lesions identified on imaging, existing lesions showing progression per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1)/imaging characteristics or by clinical criteria, lesions requiring active interventions for symptom control). * Carcinomatous meningitis. * Known or suspected hypersensitivity to ARV-6723 or pembrolizumab or any of its excipients. * Active autoimmune disease or history of autoimmune diseases that may relapse. * History of severe immune-related adverse events (irAE) attributed to prior anti-PD-1/anti-CTLA-4/anti-LAG-3 therapy. * Prior treatment with any HPK1-targeting agent * Systemic anti-cancer therapy or radiation therapy within 14 days prior to study treatment start. * Current use of any prohibited concomitant medication(s) or herbal supplements which cannot be discontinued, prior to start of study intervention and for the duration of the study. * Baseline (screening) standard 12-lead electrocardiogram (ECG) that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results.
Conditions Breast Carcinoma
Phase NA
Enrollment 800
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This clinical trial develops and studies how well mobile health (m-Health) patient navigation (PN) strategies work to improve screening and the early detection of breast cancer in women accessing primary care clinics in Kenya. Although highly curable, breast cancer kills thousands of women in developing countries yearly. Mammography (MMG) is used for the early detection of breast cancer by creating a picture of the breast using film or a computer. Despite the availability of MMG in all 47 counties in Kenya, screening remains low in eligible women. Early detection of breast cancer may also be improved through access to high quality clinical breast exams (CBE). However, primary care providers in Kenya face barriers to incorporating CBE into practice, including limited patient awareness of breast cancer screening. m-Health uses applications on mobile phones to deliver PN directly to the patients. The PN strategies in this study include digital platforms and tools to help with education, reminders, navigation, and motivation around breast cancer screening. This may improve screening and the early detection of breast cancer in women accessing primary care clinics in Kenya.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Sequential Primary purpose: Screening Masking/blinding: Single

Interventions / Regimen

  • Other: Best Practice — Receive EUC
  • Other: Discussion — Complete a focus group
  • Other: Interview - Stakeholder — Complete stakeholder interview
  • Other: Interview - Key Informant — Complete key informant interview
  • Other: Interview - Ancillary studies — Ancillary studies
  • Behavioral: Patient Navigation - C Components — Receive adapted m-Health PN strategy C components
  • Behavioral: Patient Navigation - B components — Receive adapted m-Health PN strategy B components
  • Behavioral: Patient Navigation - A components — Receive adapted m-Health PN strategy A components

Primary Outcomes

  • Adapted evidence-based intervention (EBI) delivery strategies (Aim 1) (Up to 2 years)
  • Health system resources, training, and requirements for EBI implementation (Aim 2) (Up to 4 years)
  • Access to screening mammography (MMG) for eligible asymptomatic women (Aim 3) (Up to 6 months)
  • Access to diagnostic MMG or breast ultrasound for women who have a breast abnormality identified on clinical breast examination offered at the clinic (Aim 3) (Up to 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-22
Completion: 2029-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 800 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Emory University
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Michael Chung (PRINCIPAL_INVESTIGATOR) - Emory University Hospital/Winship Cancer Institute
Contact Information
Study Contact:
Michael Chung
404-251-4012
michael.h.chung@emory.edu
Emory University Hospital/Winship Cancer Institute
Michael Chung
Emory University Hospital/Winship Cancer Institute
Interventions
  • Other: Best Practice — Receive EUC
  • Other: Discussion — Complete a focus group
  • Other: Interview - Stakeholder — Complete stakeholder interview
  • Other: Interview - Key Informant — Complete key informant interview
  • Other: Interview - Ancillary studies — Ancillary studies
Study Locations (1 sites)
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia 30322 United States
Eligibility Criteria
Inclusion Criteria: * AIM 1: All members of BREAKTHROUGH's Stakeholder Advisory Board (SAB) breast cancer working group * AIM 1: Participants (patients and health providers) from primary health care clinics in Nairobi County * AIM 1: Will include women (patients) aged over 35 years and speak either Kiswahili or English * AIM 1: Include women who: * Have never undergone MMG screening * Previously undergone MMG screening * Experienced breast abnormalities and have been referred for or undergone diagnostic investigations * Are currently undergoing or have received breast cancer treatment * AIM 1: Health care providers and breast screening facility staff (i.e. primary care clinic nurses, MMG clinic staff and technicians) will also be recruited * AIM 2: Will engage with a diverse group of local and national interagency stakeholders, Nairobi County health leadership, and health providers across different levels of the health system * AIM 3: Women aged 35 years and older who are able to provide informed consent who are attending the outpatient clinics for primary health care * AIM 4: Members of SAB breast cancer group, health facilities leadership (all health facility levels) Exclusion Criteria: * AIM 1: Those who will be unwilling to consent and those who are unable to consent will be excluded from the study * AIM 2: Those who will be unwilling to consent and those who are unable to consent will be excluded from the study * AIM 3: Women undergoing breast cancer treatment and women aged 70 years and above will be excluded * AIM 4: Members of SAB breast cancer group, and health facilities leadership who will be unwilling and unable to consent will be excluded
Conditions Insulin Resistance, Insulin Resistance a...
Phase Not Applicable
Enrollment 250
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Insulin resistance is an early etiological factor in the development of type-2 diabetes (T2D), which constitutes a large societal health burden with an expected additional rise in the years to come. Skeletal muscle is the body's largest lean tissue mass and the major site of glucose disposal in response to insulin stimulation. Prior studies have suggested that a fast skeletal muscle phenotype, including a predominant fast muscle fiber composition, reduced capillary density, low fat oxidation and muscle oxidative capacity may be implicated in insulin resistance and TD2 development. However, key questions pertain in relation to the cause and effect of these relationships as well as the interaction with potential confounders and effect-modifiers including life-style factors (e.g. diet and physical activity levels) and general participant characteristics (e.g. body composition and training status). In the present project, we therefore aim to derive muscle fiber type and extensively map the proteomic signature of the early stages of insulin resistance in a large cross-sectional study using a young and apparently healthy cohort prior to T2D development, including a thorough participant characterization. We will recruit \~250 participants (men and women) in the age of 20-30 years and conduct extensive phenotyping and tissue sampling across one laboratory-based test day and a scan visit, as well as measurements of physical activity level and glucose handling in free-living conditions with wearable sensors. The study has a longitudinal aspect as participants will be re-invited at 5-year intervals for up to 20 years to delineate the trajectory of metabolic health in relation to muscle phenotype measures. The results of the project are expected to lead to significant advancements in our understanding of the importance of muscle phenotype for early-stage insulin resistance and metabolic health trajectories. Such understanding has potentially important clinical implications, as it can open new avenues for targeted interventions and individualized early preventive strategies to counter or delay the progression of insulin resistance and associated metabolic and cardiovascular disorders.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Whole-body insulin sensitivity (At baseline and at 5-year intervals for up to 20 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-05-19
Completion: 2046-12-31
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: Not specified
Enrollment: 250 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Ghent
Collaborators: University Hospital, Ghent
Contact Information
Study Contact:
Eline Lievens, Professor
00320478312585
eline.lievens@ugent.be
Jeppe Foged Vigh-Larsen, PhD
004529870635
jeppefoged.vighlarsen@ugent.be
Eline Lievens, Professor
00320478312585
eline.lievens@ugent.be
Ghent University
Interventions
N/A
Study Locations (1 sites)
Ghent University, Ghent, East Flanders 9000 Belgium
Eligibility Criteria
Inclusion Criteria: * Sex: Males and females * Age: 20-30 years * BMI \<35 * Healthy (no diagnosed chronic disease) Exclusion Criteria: * Chronic disease deemed to affect study outcomes * Disease that increase haemorrhage risk * Daily intake of medication that could confound study outcomes * Regular smokers * Active pregnancy * Immobilization (inactivity due to injury or illness, e.g. cast or brace) for more than a week in the month prior to the study or for more than 4 weeks in the past 6 months prior to the study * Very high structured physical exercise level (\>10 h/week). * Participants not willing to adhere to standardized meal prescriptions included in the study protocols will also be excluded (due to e.g. allergies or specific dietary preferences)
Conditions Major Depressive Disorder (MDD), Treatme...
Phase PHASE1, PHASE2
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Major depressive disorder is one of the leading causes of disability worldwide, and a substantial proportion of patients do not achieve adequate improvement with conventional antidepressant treatments. Cannabidiol (CBD), a non-intoxicating cannabinoid derived from Cannabis sativa, has shown potential anxiolytic, anti-inflammatory, and neurobiological effects that may be relevant for depressive disorders. The ANANDA trial is a multicenter, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy, safety, and tolerability of full-spectrum cannabidiol oil as an adjunctive treatment in adults with treatment-resistant major depressive disorder. A total of 120 participants will be randomly assigned to receive either full-spectrum cannabidiol oil or placebo for 12 weeks while maintaining stable antidepressant treatment. Clinical assessments of depressive symptoms, anxiety, sleep quality, perceived stress, and adverse effects will be performed at baseline, Week 4, and Week 12. Blood samples will be collected at baseline and after 12 weeks to investigate inflammatory and neuroendocrine biomarkers. The primary objective is to evaluate changes in depressive symptoms after 12 weeks of treatment. Secondary objectives include the assessment of anxiety, sleep quality, perceived stress, biological markers, safety, and tolerability. The findings of this study may contribute to the development of new therapeutic approaches for treatment-resistant depression and provide additional evidence regarding the clinical use of cannabidiol in psychiatric disorders.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Full-spectrum CBD oil 100 mg/mL — Full-spectrum Cannabis sativa extract containing cannabidiol (CBD) 100 mg/mL and tetrahydrocannabinol (THC) 3.33 mg/mL, administered sublingually for 12 weeks according to a structured dose titration schedule. Treatment will begin with low doses and may be gradually adjusted based on clinical response and tolerability, respecting predefined safety limits established in the study protocol.
  • Drug: Placebo oil (MCT oil) — Placebo comparator consisting of medium-chain triglyceride (MCT) oil administered sublingually for 12 weeks according to the same dose titration schedule used in the experimental group. The placebo formulation is matched to the active intervention in appearance, color, viscosity, packaging, and administration conditions to maintain blinding throughout the study. Treatment adherence, tolerability, and adverse events will be monitored throughout the intervention period.

Primary Outcomes

  • Change in Depressive Symptom Severity Assessed by the Hamilton Depression Rating Scale (HAM-17) (Baseline, Week 4, and Week 12)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2026-06-01
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universidade do Sul de Santa Catarina
Collaborators: Federal University of Latin American Integration, Associação Cannabis Sem Fronteiras - ACSF
Contact Information
Study Contact:
Rafael Mariano Bitencourt, PhD
+55 48 9 8833-6460
bitencourtrm@gmail.com
Rafael Mariano Bitencourt, PhD
+55 48 9 8833-6460
bitencourtrm@gmail.com
Universidade do Sul de Santa Catarina - UNISUL
Interventions
  • Drug: Full-spectrum CBD oil 100 mg/mL — Full-spectrum Cannabis sativa extract containing cannabidiol (CBD) 100 mg/mL and tetrahydrocannabinol (THC) 3.33 mg/mL, administered sublingually for 12 weeks according to a structured dose titration schedule. Treatment will begin with low doses and may be gradually adjusted based on clinical response and tolerability, respecting predefined safety limits established in the study protocol.
  • Drug: Placebo oil (MCT oil) — Placebo comparator consisting of medium-chain triglyceride (MCT) oil administered sublingually for 12 weeks according to the same dose titration schedule used in the experimental group. The placebo formulation is matched to the active intervention in appearance, color, viscosity, packaging, and administration conditions to maintain blinding throughout the study. Treatment adherence, tolerability, and adverse events will be monitored throughout the intervention period.
Study Locations (1 sites)
Universidade do Sul de Santa Catarina - UNISUL, Tubarão, Santa Catarina 88704900 Brazil
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 to 69 years * Diagnosis of Major Depressive Disorder (MDD) * Persistent depressive symptoms despite ongoing antidepressant treatment * Stable antidepressant treatment for at least four weeks before enrollment * Residence in Brazil * Ability to understand study procedures and comply with study requirements * Provision of written informed consent Exclusion Criteria: * Current use of cannabis-derived products or cannabinoid-based medications * Diagnosis of bipolar disorder, schizophrenia, or other psychotic disorders * Current substance use disorder, except nicotine or caffeine * Pregnancy or breastfeeding * Severe or unstable medical conditions that may interfere with study participation * History of hypersensitivity or allergy to Cannabis sativa products or MCT oil * Active suicidal ideation or significant suicide risk requiring immediate intervention * Participation in another clinical trial within the previous 30 days * Inability to comply with study procedures or follow-up assessments
Conditions Type 2 Diabetes
Phase Not Applicable
Enrollment 2150
Locations 76 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to identify and characterize patients with known Type 2 Diabetes Mellitus (T2DM) for possible participation in ongoing or future T2DM clinical studies, and to characterize trends in key concomitant medication use in this patient population across different geographical regions.

Design

Study type: Observational Observational model: Cohort Time perspective: Cross Sectional

Interventions / Regimen

  • Other: Procedure: assessment — The approximate volume of blood required is 2 mL

Primary Outcomes

  • Patient demographics (Visit 1 (Single day))
  • Medical and surgical history (Visit 1 (Single day))
  • Concomitant medication (Visit 1 (Single day))
  • HbA1c levels (Visit 1 (Single day))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-05-06
Completion: 2027-03-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 2150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AstraZeneca
Contact Information
Study Contact:
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
Interventions
  • Other: Procedure: assessment — The approximate volume of blood required is 2 mL
Study Locations (76 sites)
Research Site, Peoria, Arizona 85382 United States
Research Site, Little Rock, Arkansas 72205 United States
Research Site, Lincoln, California 95648 United States
Research Site, Jacksonville, Florida 32256 United States
Research Site, Lake City, Florida 32055 United States
Research Site, Leesburg, Florida 34748 United States
Research Site, Ocoee, Florida 34761 United States
Research Site, Decatur, Georgia 30030 United States
Research Site, Melrose Park, Illinois 60160 United States
Research Site, El Dorado, Kansas 67042 United States
Eligibility Criteria
Inclusion Criteria: * Participants must be ≥ 18 years of age at the time of signing the ICF. * Patients with a diagnosis of T2DM, test- or documentation-confirmed as per World Health Organization or local diagnostic standards, inadequately managed with: 1. Lifestyle management alone, AND/OR 2. A stable dose of background glucose-lowering medication(s) for T2DM (As specified in the Protocol) for at least 45 days prior to signing the ICF. * Expresses interest in participating in an ongoing or future T2DM clinical study, is motivated and willing to make themselves available for the duration of the study, and is able to follow study procedures as required. * Provision of signed and dated written informed consent (As specified in the Protocol) before any study-specific procedures, sampling, or analysis. Exclusion Criteria: * Current or planned use of GLP-1 RAs prohibited in ongoing or future T2DM studies evaluating the efficacy and safety of investigational GLP-1 RAs (As specified in the Protocol). * Diagnosed with Type 1 diabetes mellitus. * Known pregnancy at the time of visit or having the intention to become pregnant.
Conditions T2DM
Phase PHASE2
Enrollment 240
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The aim of the trial is to investigate the efficacy and safety of HRS9531 tablets versus placebo in participants with type 2 diabetes mellitus who failed to achieve adequate glycemic control on lifestyle intervention alone or on a stable dose of metformin. This study will last 20 weeks.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: HRS9531 Tablet — HRS9531 Tablet dose 1
  • Drug: HRS9531 Tablet — HRS9531 Tablet dose 2
  • Drug: HRS9531 Tablet — HRS9531 Tablet dose 3
  • Drug: HRS9531 Tablet — HRS9531 Tablet dose 4
  • Drug: HRS9531 Tablet — HRS9531 Tablet dose 5
  • Drug: HRS9531 Tablet placebo — HRS9531 Tablet placebo

Primary Outcomes

  • Change in glycated hemoglobin (HbA1c) relative to baseline (Week 20.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-07-14
Completion: 2027-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 240 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Contact Information
Study Contact:
Junmeng Shi
17721288226
junmeng.shi.js12@hengrui.com
Guang Wang
Beijing Chaoyang Hospital, Capital Medical University
Xinguo Hou
Qilu Hospital of Shandong University
Interventions
  • Drug: HRS9531 Tablet — HRS9531 Tablet dose 1
  • Drug: HRS9531 Tablet — HRS9531 Tablet dose 2
  • Drug: HRS9531 Tablet — HRS9531 Tablet dose 3
  • Drug: HRS9531 Tablet — HRS9531 Tablet dose 4
  • Drug: HRS9531 Tablet — HRS9531 Tablet dose 5
Study Locations (2 sites)
Beijing Chaoyang Hospital, Capital Medical University, Beijing, Beijing Municipality 100020 China
Qilu Hospital of Shandong University, Jinan, Shandong 250012 China
Eligibility Criteria
Inclusion Criteria: 1. Male or female, aged 18 to 70 years on the day of signing the informed consent form; 2. Have a documented history of type 2 diabetes mellitus for at least 6 months at screening, diagnosed according to the criteria in Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2024 Edition); 3. HbA1c between 7.5% and 10.5% at screening; 4. Have received lifestyle intervention alone for at least 8 weeks, or stable metformin monotherapy for at least 8 weeks prior to screening. Stable treatment is defined as no change in daily drug dosage, with no planned modifications to the regimen during the entire trial period; 5. Fasting plasma glucose ≤ 15 mmol/L; 6. Body mass index (BMI) between 20.0 kg/m² and 40.0 kg/m² at screening; 7. Voluntarily sign the informed consent form before the trial, fully understand the trial content, procedures and potential adverse reactions, and be able and willing to comply with protocol requirements to complete the study; 8. Have no fertility plans from the signing of the informed consent form until 2 months after the last dose, and agree to use highly effective contraceptive measures as specified in the protocol.methods. Exclusion Criteria: 1. Participants with relevant abnormal test results at screening. 2. Participants with clinically significant abnormal findings on electrocardiogram (ECG) that, in the investigator's opinion, may compromise subject safety. 3. Participants with poorly controlled blood pressure. 4. Participants diagnosed with or suspected of having type 1 diabetes, specific types of diabetes, or secondary diabetes. 5. Participants who experienced acute diabetic complications within 6 months prior to screening. 6. Participants who experienced severe hypoglycemic events or recurrent hypoglycemic events within 6 months prior to screening. 7. Participants with severe chronic diabetic complications at screening, or non-proliferative diabetic retinopathy requiring treatment during the trial. 8. Participants with a past or known history or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2). 9. Participants with a past or known history of acute or chronic pancreatitis, pancreatic injury, acute cholecystitis, or symptomatic/treatment requiring gallbladder disease. 10. Participants with a past history of significant gastrointestinal diseases (such as severe diabetic gastroparesis, gastric outlet obstruction, inflammatory bowel disease, active ulcer, etc.), or who have undergone gastrointestinal surgery (excluding gastrointestinal polypectomy and appendectomy), or who are taking long-term medications that directly affect gastrointestinal motility. 11. Participants with a history of severe cardiovascular or cerebrovascular diseases within 6 months prior to screening. 12. Participants with known or suspected depression, bipolar disorder, suicidal ideation, schizophrenia, or other severe psychiatric disorders; or participants who are mentally incompetent, have language barriers, are unable to fully understand the trial protocol, or are unwilling to cooperate with study site staff. 13. Participants with a history of malignant tumor within 5 years prior to screening, except for cured localized cancers such as localized basal cell carcinoma of the skin, cervical carcinoma in situ, and prostate carcinoma in situ. 14. Female participants who are pregnant, breastfeeding, or planning to become pregnant during the trial. 15. Any other conditions that, in the investigator's judgment, render the subject unsuitable for participation in this clinical trial.
Conditions Stroke, Depressive Symptoms
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This pilot randomized controlled trial will evaluate the feasibility and preliminary effects of a six-week behavioral intervention designed to improve mood and daily functioning in adults who have experienced a stroke and report depressive symptoms and difficulty becoming engaged in activities after waking. Participants will be randomly assigned to either the behavioral intervention or a health education program. Assessments will be completed before and immediately after the six-week program and will include questionnaires and seven-day monitoring of sleep, activity, and mood. The study will also examine feasibility indices such as participant retention, intervention attendance, acceptability, and preliminary changes in mood.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Morning Activation Program — A six-week individualized behavioral program delivered in weekly sessions of approximately 60 minutes. The program is designed to support engagement in daily activities after waking, establish consistent daily routines, and improve mood and functioning after stroke. Sessions will be tailored to participants' needs and abilities.
  • Behavioral: Health Education Program — A six-week health education program delivered in weekly sessions of approximately 60 minutes. The program will provide general information relevant to health and recovery after stroke and will be matched to the experimental program in session frequency and duration. It will not include the individualized behavioral strategies provided in the experimental arm.

Primary Outcomes

  • Recruitment Rate (From the start of recruitment until enrollment of the final participant.)
  • Retention Rate (Immediately after completion of the 6-week intervention)
  • Intervention Attendance (Throughout the 6-week intervention period)
  • Intervention Acceptability (Immediately after completion of the 6-week intervention)
  • Participants Experiencing Adverse Events (From enrollment through completion of the immediate post-intervention assessment.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-05-15
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Hong Kong Polytechnic University
Contact Information
Study Contact:
Stephen Lau
+852 2766 4283
chun-lun-stephen.lau@polyu.edu.hk
Stephen Lau
+852 2766 4283
chun-lun-stephen.lau@polyu.edu.hk
The Hong Kong Polytechnic University
Stephen Lau, PhD
The Hong Kong Polytechnic University
Interventions
  • Behavioral: Morning Activation Program — A six-week individualized behavioral program delivered in weekly sessions of approximately 60 minutes. The program is designed to support engagement in daily activities after waking, establish consistent daily routines, and improve mood and functioning after stroke. Sessions will be tailored to participants' needs and abilities.
  • Behavioral: Health Education Program — A six-week health education program delivered in weekly sessions of approximately 60 minutes. The program will provide general information relevant to health and recovery after stroke and will be matched to the experimental program in session frequency and duration. It will not include the individualized behavioral strategies provided in the experimental arm.
Study Locations (1 sites)
The Hong Kong Polytechnic University, Hong Kong, Hong Kong
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older. * History of stroke at least 6 months before enrollment. * Patient Health Questionnaire-9 score of 10 or higher. * Difficulty getting started or engaging in activities in the morning. * Able to provide informed consent. Exclusion Criteria: * Conditions that would interfere with study participation. * Neurological condition other than stroke. * Currently receiving psychological therapy for depression. * Significant cognitive impairment or dementia. * Current or past diagnosis of psychosis, bipolar disorder, or mania. * Hospitalization that would interfere with study participation. * Acute or significant suicidal ideation * Alcohol or substance use problems within the past month. * Use of antidepressant or anti-anxiety medication unless the dosage has been stable for at least 4 weeks and no changes are planned during the study.
Conditions Low-Risk, Early Stage Breast Cancer
Phase NA
Enrollment 400
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The FDA has granted marketing authorization for the ProSense® Cryoablation System for the local treatment of patients aged 70 years or older with low-risk early-stage breast cancer who are also receiving adjuvant hormone therapy. This clinical trial is designed to collect additional data on the safety and effectiveness of cryoablation when used as part of routine clinical care. Specifically, the study will evaluate recurrence rates following the procedure for up to 5 years post-treatment. In addition, linkage to claims data will be used to assess long-term outcomes, including breast cancer-related surgeries, mammograms and other breast imaging procedures, breast biopsies, and all-cause mortality.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Cryoablation — Cryoablation procedure, without resection, using the IceCure Medical ProSense® Cryoablation System. Patients will be also provided with adjuvant endocrine therapy for 5 years post-treatment. The IceCure ProSense® cryoablation system is intended for cryogenic destruction of tissue by the application of extreme cold temperatures.

Primary Outcomes

  • Confirmed Ipsilateral Breast Tumor Recurrence (IBTR) Rate (5 Years)
  • Confirmed and suspected Ipsilateral Breast Tumor Recurrence (IBTR) Rate (5 Years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-17
Completion: 2034-09
Eligibility
Age: 70 Years and older
Sex: ALL
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: IceCure Medical Ltd.
Contact Information
Study Contact:
Eidan Loushi Clinical Operations Specialist, M.Sc.
+972-548118632
eidanl@icecure-medical.com
Ronit Lipson, Clinical Trial Manager
+972-522337768
ronitl@Icecure-medical.com
Lily Villalobos
818-539-9185
villall3@ah.org
Glendale Adventist Medical Center d/b/a Adventist Health Glendale
Interventions
  • Device: Cryoablation — Cryoablation procedure, without resection, using the IceCure Medical ProSense® Cryoablation System. Patients will be also provided with adjuvant endocrine therapy for 5 years post-treatment. The IceCure ProSense® cryoablation system is intended for cryogenic destruction of tissue by the application of extreme cold temperatures.
Study Locations (2 sites)
Glendale Adventist Medical Center d/b/a Adventist Health Glendale, Glendale, California 91206 United States
The West Clinic, PC dba West Cancer Center, Germantown, Tennessee 38138 United States
Eligibility Criteria
Inclusion Criteria: 1. Provision of a signed and dated informed consent form. 2. Age ≥70 3. Diagnosis of invasive ductal breast carcinoma (IDC) by core needle biopsy, meeting the following criteria: * Unifocal primary disease * Tumor size ≤1.5 cm in greatest diameter * Estrogen receptor positive, Progesterone receptor positive, and HER2 negative * Low-risk tumor biology, defined as Ki67\<15% or confirmed by genomic testing. In cases where Ki67 is ≥15%, low-risk status must be confirmed by genomic testing, which will prevail. 4. Lesions must be sonographically visible at the time of treatment 5. Clinically negative lymph node (N0). Exclusion Criteria: 1. Presence of lobular carcinoma. 2. Presence of microinvasion or invasive breast carcinoma with extensive intraductal component (EIC), defined as DCIS component comprising ≥25%. 3. Evidence of lymphovascular invasion. 4. Presence of multifocal and/or multicentric breast cancer. 5. Presence of multifocal suspicious calcifications. 6. Presence of inflammatory features. 7. Previous ipsilateral breast radiation 8. Neoadjuvant endocrine treatment is provided to reduce the tumor size. 9. Prior or concurrent neoadjuvant chemotherapy, biological therapy, or other targeted neo-therapies. 10. Prior en bloc open surgical biopsy and/or lumpectomy for diagnosis/treatment of the index breast cancer. 11. Allergy to local anesthesia. 12. Any other reason defined as inoperable declared by a physician.